Endometrial Cancer - Pipeline Insight, 2025: Immunotherapy and Targeted Agents Drive Innovation in Advanced and Recurrent Disease Settings | DelveInsight

Endometrial cancer, the most common gynecologic malignancy in developed countries, is witnessing a shift in treatment dynamics, especially in advanced and recurrent stages where standard therapies offer limited survival benefits. The rise of molecularly guided therapies and checkpoint inhibitors is reshaping this therapeutic frontier.

By 2025, the pipeline for endometrial cancer includes over 45 active candidates, with a strong focus on PD-1/PD-L1 inhibitors, PI3K/AKT/mTOR inhibitors, hormone receptor-targeted therapies, and combinations tailored to MSI-H and p53-mutated tumors. Companies such as Eisai, GSK, Seagen, Gilead Sciences, and Regeneron are leading the charge in late-stage development programs.

DelveInsight's "Endometrial Cancer - Pipeline Insight, 2025" presents a detailed analysis of clinical advances, biomarker-led treatment strategies, and the growing role of immunotherapy across treatment lines. The report also tracks recent FDA designations and ongoing registrational trials expected to redefine standards of care.

With a push toward biomarker stratification and earlier-line immunotherapy integration, the endometrial cancer pipeline is evolving rapidly, offering patients renewed hope for personalized, longer-lasting outcomes.

Interested in learning more about the current treatment landscape and the key drivers shaping the endometrial cancer pipeline? Click here: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Endometrial Cancer Pipeline Report
• DelveInsight's endometrial cancer pipeline analysis depicts a strong space with 45+ active players working to develop 50+ pipeline drugs for endometrial cancer treatment.
• The leading endometrial cancer companies include Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others are evaluating their lead assets to improve the endometrial cancer treatment landscape.
• Key endometrial cancer pipeline therapies in various stages of development include LENVIMA, Mirvetuximab soravtansine, XMT 1660, VLS-1488, ZW25, XB002, Trastuzumab deruxtecan, TQB2450, TPST-1495, TOS-358, TORL-1-23, TNG260, TH1902, SYD985, SKB264, SGN-STNV, SGNB 7H4V, Selinexor, RGX-104, Dordaviprone, and others.
• In March 2025, updated Phase III data from the ENGOT‐EN6‐NSGO/GOG‐3031/RUBY trial showed that dostarlimab‐gxly (Jemperli) combined with carboplatin and paclitaxel extended median duration of response (DOR) by 4.4 months versus chemotherapy alone in advanced or recurrent endometrial cancer.
• In February 2025, the OncoSignature multiplex immunofluorescence assay received FDA breakthrough device designation for identifying endometrial cancer patients who may benefit from ACR-368 (prexasertib) treatment.
• In February 2025, Acrivon Therapeutics announced that the FDA granted Breakthrough Device designation for its ACR-368 OncoSignature assay. This multiplex immunofluorescence assay is designed to identify endometrial cancer patients who may benefit from ACR-368 treatment.

Request a sample and discover the recent breakthroughs happening in the endometrial cancer pipeline landscape at https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Endometrial Cancer Overview
Endometrial cancer is the most common gynecologic malignancy in developed countries, primarily affecting the lining of the uterus (endometrium). It typically arises in postmenopausal women, although younger women can also be affected. The majority of cases are diagnosed at an early stage due to abnormal uterine bleeding, which often prompts timely medical evaluation.

There are two main types: Type I, which is estrogen-dependent and often linked to obesity, diabetes, and unopposed estrogen exposure, and Type II, which is more aggressive and estrogen-independent. While early-stage endometrial cancer has a favorable prognosis with surgery alone, advanced or recurrent disease often requires a multimodal approach including radiation, chemotherapy, and emerging targeted therapies. Advances in molecular profiling and immunotherapy are helping to shape more personalized treatment strategies in this evolving therapeutic landscape.

Find out more about endometrial cancer medication at https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Endometrial Cancer Treatment Analysis: Drug Profile
Selinexor: Karyopharm Therapeutics
Selinexor (marketed as XPOVIO) is a first-in-class, oral selective inhibitor of nuclear export (SINE) that targets exportin 1 (XPO1). By binding to and inhibiting XPO1, selinexor promotes the accumulation of tumor suppressor proteins in the nucleus, leading to cancer cell apoptosis. It is being studied as a maintenance therapy in patients with advanced or recurrent endometrial cancer, particularly those with TP53 wild-type tumors. Findings from the Phase III SIENDO trial have demonstrated encouraging improvements in progression-free survival (PFS) in this subgroup, and the drug is currently in late-stage (Phase III) clinical development for endometrial cancer.

Abemaciclib: Eli Lilly and Company
Abemaciclib, a CDK4/6 inhibitor developed by Eli Lilly, has shown encouraging activity in combination with hormonal therapy for patients with recurrent estrogen receptor (ER)-positive endometrioid endometrial cancer (EEC). In a Phase II trial, abemaciclib combined with hormonal agents achieved a clinical benefit rate of 67%, with observed partial and complete responses and a median PFS of 6.1 months. Another study using abemaciclib and letrozole reported a 30% objective response rate and a median PFS of 9.1 months. When metformin was added to the regimen, outcomes improved further due to multi-pathway targeting of ER, CDK4/6, and PI3K. These results highlight abemaciclib-based combinations as a promising treatment avenue in ER-positive EEC, with ongoing studies continuing to evaluate its efficacy and safety.

NP137: NETRIS Pharma
NP137 is a humanized IgG1 monoclonal antibody developed by NETRIS Pharma that targets netrin-1, a guidance cue protein overexpressed in many tumors and linked to treatment resistance and disease progression. NP137 aims to restore apoptosis and counter epithelial-to-mesenchymal transition (EMT), mechanisms commonly implicated in therapeutic resistance. Preclinical and early clinical data indicate that NP137 has anti-tumor activity both as a monotherapy and in combination with chemotherapy or immunotherapy. With a favorable safety profile, the drug is currently in Phase II development for endometrial cancer.

Learn more about the novel and emerging endometrial cancer pipeline therapies at https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Endometrial Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

By Molecule Type
• Small molecules
• Natural metabolites
• Monoclonal antibodies

Scope of the Endometrial Cancer Pipeline Report
• Coverage: Global
• Key Endometrial Cancer Companies: Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Key Endometrial Cancer Pipeline Therapies: LENVIMA, Mirvetuximab soravtansine, XMT 1660, VLS-1488, ZW25, XB002, Trastuzumab deruxtecan, TQB2450, TPST-1495, TOS-358, TORL-1-23, TNG260, TH1902, SYD985, SKB264, SGN-STNV, SGNB 7H4V, Selinexor, RGX-104, Dordaviprone, and others.

Dive deep into rich insights for drugs used for endometrial cancer treatment, visit: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Endometrial Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Endometrial Cancer Pipeline Therapeutics
6. Endometrial Cancer Pipeline: Late-Stage Products (Phase III)
7. Endometrial Cancer Pipeline: Mid-Stage Products (Phase II)
8. Endometrial Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.